1. Prediction of Successful Liberation from Continuous Renal Replacement Therapy Using a Novel Biomarker in Patients with Acute Kidney Injury after Cardiac Surgery-An Observational Trial.
- Author
-
Tichy J, Hausmann A, Lanzerstorfer J, Ryz S, Wagner L, Lassnigg A, and Bernardi MH
- Subjects
- Humans, Male, Female, Aged, Middle Aged, Prospective Studies, Enkephalins metabolism, Postoperative Complications etiology, Postoperative Complications diagnosis, Postoperative Complications therapy, Protein Precursors metabolism, Protein Precursors blood, Renal Replacement Therapy methods, Acute Kidney Injury etiology, Acute Kidney Injury therapy, Acute Kidney Injury diagnosis, Biomarkers, Cardiac Surgical Procedures adverse effects, Continuous Renal Replacement Therapy methods
- Abstract
An acute kidney injury (AKI) is the most common complication following cardiac surgery, and can lead to the initiation of continuous renal replacement therapy (CRRT). However, there is still insufficient evidence for when patients should be liberated from CRRT. Proenkephalin A 119-159 (PENK) is a novel biomarker that reflects kidney function independently of other factors. This study investigated whether PENK could guide successful liberation from CRRT. Therefore, we performed a prospective, observational, single-center study at the Medical University of Vienna between July 2022 and May 2023, which included adult patients who underwent cardiac surgery for a cardiopulmonary bypass; patients on preoperative RRT were excluded. The PENK levels were measured at the time of AKI diagnosis and at the initiation of and liberation from CRRT, and were subsequently compared to determine whether the patients were successfully liberated from CRRT. We screened 61 patients with postoperative AKI; 20 patients experienced a progression of AKI requiring CRRT. The patients who were successfully liberated from CRRT had mean PENK levels of 113 ± 95.4 pmol/L, while the patients who were unsuccessfully liberated from CRRT had mean PENK levels of 290 ± 175 pmol/L ( p = 0.018). For the prediction of the successful liberation from CRRT, we found an area under the curve of 0.798 (95% CI, 0.599-0.997) with an optimal threshold value of 126.7 pmol/L for PENK (Youden Index = 0.53, 95% CI, 0.10-0.76) at the time of CRRT liberation (sensitivity = 0.64, specificity = 0.89). In conclusion, PENK is a novel biomarker that has the potential to predict the successful liberation from CRRT for patients with AKI after cardiac surgery.
- Published
- 2024
- Full Text
- View/download PDF